Portal de Periódicos da CAPES

Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient

2017; Wiley; Volume: 42; Issue: 5 Linguagem: Inglês

10.1111/jcpt.12546

1365-2710

Chiara Taibi, Massimo Tempestilli, Antonio D’Avolio, Anna Rosa Garbuglia, Amedeo De Nicolò, Marzia Montalbano, Gianpiero D’Offizi,

Biochemical and Molecular Research

The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients.We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment.This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.